Valbiotis SA (ALVAL.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALVAL.PA in your mock portfolio yet.
Valbiotis SA is currently loss-making, as reflected by its negative EPS and PE ratio. The absence of profitability suggests the business is still in an investment or development phase, with no clear evidence yet of a transition to sustainable earnings. From a pure financial-performance standpoint, the risk profile remains elevated.
The stock has risen 11.6% over the last month, showing short-term positive momentum. However, it is trading slightly below its 200-day moving average, which tempers the bullishness and suggests the longer-term trend is still fragile or sideways. Overall, technicals point to a tentative stabilization rather than a clear uptrend.
Alternative data for Valbiotis SA show a modest digital footprint with relatively stable but not rapidly growing engagement. Website traffic is meaningful for a small-cap, but hiring is flat at zero openings and social media followings are small with only marginal growth. These signals suggest limited near-term business expansion momentum, but not a collapse in interest.
Taken together, Valbiotis SA’s negative earnings, lack of visible hiring expansion, and only modest alternative-data traction point to a cautious outlook. While the recent 1‑month price rebound and proximity to the 200‑day moving average suggest some stabilization, they are not yet supported by clear signs of improving fundamentals. The balance of evidence leans toward a bearish stance, with the stock reliant on future catalysts rather than current performance.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started